Christel Menet
Chief Scientific Officer Confo Therapeutics
Christel joined Confo as CSO in 2016. She was one of the first chemists to join Galapagos and later advanced to Director of Medicinal Chemistry.
She is the inventor of filgotinib (Jyseleca), commercialized for treatment of moderate to severe active rheumatoid arthritis. Prior to Galapagos, Christel worked at Faust Pharmaceuticals (now Domain Therapeutics), a biotechnology company specializing in GPCR drug discovery. She is an inventor on over 25 patent applications and brings over 20 years of R&D experience to Confo.
Christel completed a PhD in Organic Chemistry at the University of Manchester in the lab of Prof Jonathan Clayden.
Seminars
Wednesday 3rd March 2027
Panel Discussion: Comparing Small Molecules, Peptides & Antibodies to Identify the Optimal Modality for Clinical, Commercial & Patient Success
3:15 pm
- Which modality delivers the greatest advantage across efficacy, safety, tissue penetration and durability, and does the answer depend on the target?
- How much should patient-centric considerations such as dosing frequency, convenience and route of administration influence development decisions?
- When evaluating a new GPCR program, how much does modality choice influence commercial differentiation, partnering opportunities and long-term value creation?
Thursday 4th March 2027
Advancing a First-in-Class SSTR5 Agonist Antibody for Post-Bariatric Hypoglycemia
2:00 pm
- Progressing Confo’s lead SSTR5 agonist antibody from discovery through candidate nomination and IND-enabling studies
- Demonstrating how selective GPCR agonist antibodies can restore glycemic control in post-bariatric hypoglycemia through targeted modulation of insulin and incretin signaling
- Sharing scientific and translational learnings from advancing one of the field’s most advanced GPCR agonist antibody programs toward clinical development
